



(A company limited by guarantee)

**Registered Charity Number: 1082750
Registered Company Number: 04061607**

AUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED

31ST MARCH 2021

The Magdi Yacoub Institute Contents

	Page
Legal and Administrative Information	1
Trustees Report	2 - 7
Independent Auditors Report	8 - 11
Statement of Financial Activities	12
Balance Sheet	13
Statement of Cash Flows	14
Notes to the Financial Statements	15 - 25

The Magdi Yacoub Institute
Legal and Administrative Information

Company Registration Number	04061607
Charity Registration Number	1082750
Trustees	Mr Alan Hargreaves Mr Asghar Khaghani Professor Kim Fox Dr Magdy Ishak Professor Sir Magdi Yacoub Dr Assem Allam
Chief Executive	Dr Magdy Ishak
Company Secretary	Mr Alan Hargreaves
Registered Office	Heart Science Centre Harefield Hospital Hill End Road Harefield Uxbridge UB9 6JH
Bankers	NatWest Bank plc Rickmansworth 159 High Street Rickmansworth Hertfordshire, WD3 1AR
Solicitors	Charles Russell Speechlys LLP 5 Fleet Street London EC4M 7RD
Auditors	Moore Kingston Smith LLP Devonshire House 60 Goswell Road London EC1M 7AD

The Magdi Yacoub Institute

Report of the Trustees

The Trustees, who are directors for Companies Act purposes, present their report and financial statements for The Magdi Yacoub Institute ('the Charity') for the year ended 31st March 2021.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Nature of governing document

The Magdi Yacoub Institute is a registered charity (Charity Commission Registration Number 1082750) and was incorporated as a company limited by guarantee on 30th August 2000 (Company Registration Number 04061607). It is governed by the Memorandum and Articles of Association.

The Board of Trustees comprise the Members of the Magdi Yacoub Institute. Members of the charitable company guarantee to contribute an amount not exceeding £1 to the assets of the charitable company in the event of winding up. The total number of such guarantees at 31st March 2021 was 7 (2020: 8).

Recruitment and appointment of Trustees

Trustees are recruited through contacts of the current Board members. Potential trustees are interviewed by the Executive Committee. Trustees are appointed by the Board of Trustees.

Policies and procedures for induction and training of Trustees

Trustees are invited to attend the Institute to meet the staff and have induction meetings with senior management team members. Trustees are able to undertake training as deemed necessary.

Organisational structure and how decisions are made

The Trustees are the Directors and Members of the company limited by guarantee. The Trustees who have served during the year and since the year end are listed below:-

The Earl of Gowrie (deceased 24 September 2021)

Mr Alan Hargreaves

Mr Asghar Khaghani

Professor Kim Fox

Dr Magdy Ishak

Dr Rosemary Radley-Smith (deceased 1 August 2020)

Professor Sir Magdi Yacoub

Dr Assem Allam

No member of the Board receives any remuneration for their services. The Board meets regularly, with day to day management delegated to a management committee consisting of the Director of Research (Sir Magdi), Deputy Director of Research (Dr Adrian Chester) and the Chief Executive (Dr Magdy Ishak) operating under a scheme of delegation. A Finance Committee consisting of the Chief Executive, Company Secretary (Alan Hargreaves) and an Executive Committee consisting of the Chairman, Director of Research and the Chief Executive are able to take urgent decisions as appropriate which are ratified at the next Board Meeting. This committee propose the pay and remuneration which is approved by the Board. The Scientific and Operational roles reflect the Academic structure set by NHLI (Imperial College) and follow their grading structure for KPI's and salary. Both Research and operational roles are paid according to the corresponding levels of responsibilities described in the NHLI job families. The performance is measured continually by various KPI's which are publications in leading international journals, presentations at meetings, external grant funding and conducting collaborative research with other institutions.

Connections to a wider network

The Magdi Yacoub Institute has no formal links with other organisations but works closely with the National Heart & Lung Institute and the Royal Brompton and Harefield NHS Trust. Professor Sir Magdi Yacoub is also Founder and Trustee of the Chain of Hope. Dr Magdy Ishak, fellow of the Royal Society of Medicine and Freeman of the City of Glasgow holds the post of Chairman of the Magdi Yacoub Foundation ("MYF") in Egypt and Professor Sir Magdi Yacoub as Research & Medical Director. Dr Magdy Ishak is the Chairman of Heart Biotech and Professor Sir Magdi Yacoub is the Research Director of Heart Biotech.

The Magdi Yacoub Institute

Report of the Trustees

Objectives of The Magdi Yacoub Institute

The objectives in the Memorandum of Association are:

"To carry out research into all aspects of human heart, lung and other disease including prevention, treatment and rehabilitation, for the benefit of the public by:

(i) undertaking and promoting research (and making the useful results thereof publicly available) in relation to cardiac and transplant surgery, human heart valves and tissue engineering, circulatory support, immunology of heart and lung disease, biochemistry of heart failure, biology of human blood vessels, molecular aspects of heart disease, metabolism of the human heart and lung, transplant medical management, genetic research (in all its forms) and any other medical matter which might effect or affect an improvement in human health and wellbeing;

(ii) relieving persons suffering from heart or other diseases by enabling transplant and other operations to be carried out and associated care and treatment to be provided at Harefield Hospital or at such other site as may be convenient or appropriate;

(iii) providing and constructing amenities, equipment and facilities within the Harefield Hospital site or any linked establishments or other appropriate site or sites for the treatment and research into care and relief of persons suffering from heart or other disease who may require or who are to undergo or who have undergone transplant or other surgery; and

(iv) "any other means which appear convenient or appropriate from time to time."

Charity's Aims

The aim of the Magdi Yacoub Institute is to undertake and advance world class research into the causes and nature of heart disease, including its prevention and treatment for the benefit of humanity. Working in collaboration with other public and private organisations, as well as individuals from across the world, the Institute raises and receives funding to finance its operations and activities. The Institute initiates and promotes innovative research programmes, organising scientific leadership and direction, facilities, staff, equipment and research grants in pursuit of its aims and visions.

Objectives for the year

The objectives for the year were to continue to progress our overall research programme focused around: heart failure, tissue engineering and transplantation. The work streams in this areas are detailed below in our activities.

Charity's strategies and significant activities

The main activities have been to progress research and to review a structure to have scientific alliances with key institutes to advance the science. Alongside these work activities :

Regenerative Biology and Cardiovascular Cell Engineering. The application of stem cell biology and its fruition in the clinic demands a range of talent, depth of expertise and commitment to systematic investigation, using a combination of cell and gene therapeutic strategies. Working with an international team led by Professor Sir Magdi Yacoub, the potential crosstalk between these cell lineages in development and disease continues to be explored and exploited to generate new avenues to therapy for hypertrophic cardiomyopathy.

Tissue Engineering. Our research in tissue engineering is aimed at the development of a viable cardiac valve capable of reproducing the sophisticated functions of the normal valve. This research is based on understanding the specific cellular and molecular characteristics of the component parts, during development and in the adult, on examining the properties of stem cells and their suitability for deriving valve tissue and of examining the optimal cellular environment and scaffolds for engineering valve tissue.

Transplantation. Transplant related research continues in addressing several current issues, including chronic rejection, the role of endothelial cells in rejection, metabolic function in xenotransplantation and importantly organ resuscitation.

The Magdi Yacoub Institute

Report of the Trustees

Valve Research. The Valve Research Group is uncovering the multicellular components of valve form and function and the molecular pathways that mediate vascular protection. Studies on the biology of heart valves continue, with a current focus on the role of mechanotransduction. The work is continuing on the British Heart Foundation grant that was obtained. We have had a number of visiting undergraduate and work experience students working in the laboratory over the course of the year who have contributed to a number of different projects, some of which also relate to the Tissue Engineering project.

Cardiac Biophysics This division focuses on two main research programs.

- 1) Myofilament dysfunction in heart failure: This research program is focused on the impact of contractile protein post-translational modifications on myofilament activation/relaxation dynamics with the ultimate goal to achieve a full understanding of contractile protein structure-function relationships in striated muscle.
- 2) Frank-Starling's Law of the Heart & Myofilament function: Ventricular filling modulates cardiac pump function; one of the underlying cellular mechanisms is the modulation of myofilament Ca^{2+} sensitivity by sarcomere length. Here we focus on elucidation of the underlying molecular mechanisms. Both research programs make full use of the tools of modern biology, such as molecular biology, transgenic mouse models, recombinant DNA protein manufacture, isolated muscle biophysics, and proteomic analyses.

Volunteer Help

The Magdi Yacoub Institute does not utilise volunteer help with the exception of the time dedicated by its Trustees.

Grant making policy

The Magdi Yacoub Institute supports research by directly employing staff as well as making awards to the National Heart & Lung Institute ("NHLI") (Imperial College) for the cost of consumables for the staff engaged in research at the Heart Science Centre, Harefield. The salaries of a small number of some staff employed by Imperial College and the Royal Brompton & Harefield Hospital Trust are also recharged to the Institute. Support is also given to facilitate collaboration with research with the Aswan Heart Centre / Magdi Yacoub Foundation and tissue engineering, genetic studies into cardiomyopathy and developmental dynamics.

REVIEW OF ACHIEVEMENTS AND FINANCIAL ACTIVITY

The Tissue Engineering project continues to make progress, with a second trial in sheep completed, with the valve being implanted for 6-12 months nearing completion. In parallel to this a significant amount of work has been undertaken to standardise the valve production process so that it complies with GLP regulations. The group also plan to obtain a Haemodynamic Valve Testing Rig, so that haemodynamic data for the tissue engineered valve that is required for FDA approval for use of the valve in clinical trials.

The application to the BHF for a project to investigate the role of angiotensin II in valve calcification grant was successful, with £130,000 being awarded over 2 years. The grant started in October 2020.

The 9th Heart Valve Biology & Tissue Engineering meeting at the Como Place Hotel, in Como Italy at the end of October 2020 was cancelled due to the COVID-19 pandemic. Plans are now being made to hold the next meeting in Greece in 2022.

Many activities in the Institute were restricted by the effects of the pandemic. We were unable to accept any Nuffield students or visiting researchers over the summer months. The HSC Committee implemented a Covid Safe Risk Assessment, which allowed staff to return to work after the first lockdown in June, and then continue to work throughout the rest of the year. With help from the RBH Trust all MYI staff have received the Covid vaccination.

The Magdi Yacoub Institute

Report of the Trustees

REVIEW OF ACHIEVEMENTS AND FINANCIAL ACTIVITY (Cont)

A paper on the expression and function of stretch activated ion channels, based on the work from Hessah Alshammani PhD thesis, was published in Plos One. Dr Chester, together with a Professor from Houston, Texas, wrote an invited review in Frontier Cardiovascular Research on the relevance of heart valve biology to tissue engineering.

The Leducq grant continues to make good scientific progress. The team continues to publish papers in leading journals. The Institute has received substantial donations to support the advancement of research from personal donors.

Research Support and Equipment purchases

Funding was made available for the running and maintenance of the MYI laboratories. The only significant equipment purchased in year was a Pulse Duplicator which was used within the heart biotech project.

Results for the year are shown in the Statement of Financial Activities on page 12.

Based on total incoming resources of £1,105,100 and total resources expended of £1,229,427, the Charity made a deficit of £124,327 (2020: deficit of £192,784). Combined unrestricted and restricted funds of £4,958,012 (2020: £5,082,339) have been carried forward. At the year end total restricted funds were £374,338 (2020 £89,679).

The principal sources of funding during the year were from:

- a. £119,714 Coronavirus Job Retention Scheme Grants
- b. £ 289,625 Magdi Yacoub Foundation recharged expenses
- c. £329,590 Magdi Yacoub Global Foundation - research grants
- d. £122,808 Heart Biotech - restricted funds
- e. £125,000 Eva Pharma - donation for research

Reserves Policy

The Institute's policy with regard to reserves is to make suitable investment in ongoing development of the charity whilst maintaining adequate funds to deal with current and medium term needs. Free reserves at the year end excluding designated funds and restricted funds are £768,159 (2020: £1,098,245).

The Trustees wish to have a minimum of £360,000 in reserves to cover closure commitment. The Trustees agreed that this would not be held within the funds of the Magdi Yacoub Institute but with partners in the USA. Our partner in the USA MYGHF have committed to cover these costs in the event of closure. The free reserves calculated by the Charity are above the level set by the trustees and they are satisfied with the current level of reserves.

Fundraising policy

Magdi Yacoub Institute has a cost of raising funds in the financial statements in relation to generating income from donors. The charity does not utilise external professional fundraisers or commercial participators to carry out fundraising activity and does not engage in face-to-face or telephone fundraising. We aim to build and maintain solid partnerships with our supporters and do not undertake activities to raise funds from those that could be classified as "vulnerable people". Any approach to fundraising would take account of the Code of Fundraising Practice issued by the Fundraising Regulator. Magdi Yacoub Institute has received no complaints about its fundraising activities either during the financial year or subsequently.

The Magdi Yacoub Institute

Report of the Trustees

Risk Management

In March 2021, the Trustees completed its annual review of the Institute's risk management strategy in accordance with the requirements of the SORP. Each identified risk is classified into one of the following categories:

Governance: Trustee appointments, decision making and possible conflicts of interest.

Operational: Disaster recovery. Health & Safety issues.

Regulatory Framework: Compliance with existing legislation and regulations.

External: Relationship with the NHS and Imperial College.

Financial: Reduction in investment income, donations and grants.

Fundraising issues: Loss of key supporters. Appropriate fundraising strategy.

In the course of the review, the Trustees have determined the major risks to which the Institute is exposed, the potential impact if an individual risk materialises, and which mitigating action is to be taken, by whom, in order to reduce the risk to a level which the Trustees consider to be acceptable. The position is recorded in a risk register which is used by management and will continue to be formally reviewed annually.

The COVID-19 pandemic posed a slight risk to the MYI with respect to impeding Professor Yacoub's ability to travel and meet donors. In order to protect the staff the Heart Science Centre operated on a reduced capacity, with a small number of staff going in to carry out essential work keeping the BioBank of research samples safe and protecting the fabric of the building and the equipment within. A couple of key staff were in the high risk groups and the loss of any of these staff would have had a negative impact on the Charity.

Public Benefit

The Trustees have considered the Charity Commissioner's general guidance on public benefit when reviewing the Institute's aims and objectives and planning future activities. The aim of the Institute is to undertake and advance world class research into the causes and nature of heart disease, including its prevention and treatment, for the benefit of humanity. To this end, advances in research are published and available to others with similar aims.

The Institute collaborates with other organisations undertaking research in third world countries and assists in advancing their research capability. There are no exclusions to those who can benefit from the results of the Institute's research and beneficiaries will be worldwide. There are no private benefits gained, other than incidental, by those engaged in research at the Institute.

Plans for the Future

For the year to 31st March 2022, the Trustees have set the following key performance indicators (KPI):

- 1 To continue collaboration with NHLI and MYF plus our partner in America MYGHF
- 2 The plan to expand science is underway with the collaboration with AHC
- 3 Expand the Website to develop it into an open access knowledge hub for dissemination of the Institutes activities

Our aim remains to progress research projects and this data is being gathered. The team are progressing well with grant submissions and articles being cited in renowned journals.

The charity will continue to work in a Covid secure way until the pandemic is over.

The Magdi Yacoub Institute

Report of the Trustees

Disclosure of Information to Auditors

So far as the trustees are aware, there is no relevant audit information of which the company's auditors are unaware. The trustees have taken all the steps that they ought to have taken as trustees in order to make themselves aware of any relevant audit information and to establish that the company's auditors are aware of that information.

Statement of Trustees' Responsibilities

The trustees (who are also directors of The Magdi Yacoub Institute for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice. Company law requires trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charitable company and of the incoming/outgoing resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

These accounts have been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006.

By order of the board



Trustee & The Director of Research
Professor Sir Magdi Yacoub

Date: 19 December 2021

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE MAGDI YACOUB INSTITUTE

Opinion

We have audited the financial statements of the Magdi Yacoub Institute ('the company') for the year ended 31 March 2021 which comprise the Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 'The Financial Reporting Standard Applicable in the UK and Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 March 2021 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs(UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of financial statements section of our report. We are independent of the Corporation in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE MAGDI YACOB INSTITUTE

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' annual report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Trustees' Annual Report and from preparing a Strategic Report.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 7, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE MAGDI YACOUB INSTITUTE

implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

- We obtained an understanding of the legal and regulatory requirements applicable to the company and considered that the most significant are the Companies Act 2006, the Charities Act 2011, UK financial reporting standards as issued by the Financial Reporting Council and UK taxation legislation.
- We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance.
- We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.
- We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations.
- Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the charitable company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE MAGDI YACOUB INSTITUTE

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company and charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

A handwritten signature in black ink that reads "Moore Kingston Smith LLP" with a small "2" as a subscript under the "P".

Luke Holt (Senior Statutory Auditor)
for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

Devonshire House
60 Goswell Road
London
EC1M 7AD

Date 22 December 2021

The Magdi Yacoub Institute
Statement of Financial Activities
(including Income and Expenditure account)
For the year ended 31st March 2021

	Notes	Unrestricted £	Restricted £	2021 Total £	2020 Total £
Income from:					
Grants and donations	2a	559,484	545,240	1,104,724	1,177,005
Legacies	2b	-	-	-	-
Investment income	3	376	-	376	1,581
Total income		<u>559,860</u>	<u>545,240</u>	<u>1,105,100</u>	<u>1,178,586</u>
Expenditure on:					
Raising funds		162,405	-	162,405	147,501
Charitable activities:					
Research		713,567	353,455	1,067,022	1,223,869
Total expenditure	4	<u>875,972</u>	<u>353,455</u>	<u>1,229,427</u>	<u>1,371,370</u>
Net income/(expenditure)	5	(316,112)	191,785	(124,327)	(192,784)
Transfers between funds	11/12	95,518	(95,518)	-	-
Net movement in funds		<u>(220,594)</u>	<u>96,267</u>	<u>(124,327)</u>	<u>(192,784)</u>
Reconciliation of Funds					
Balance brought forward at 1 April 2020		<u>4,992,660</u>	<u>89,679</u>	<u>5,082,339</u>	<u>5,275,123</u>
Balance carried forward at 31 March 2021	11/12	<u>4,772,066</u>	<u>185,946</u>	<u>4,958,012</u>	<u>5,082,339</u>

The accompanying notes on pages 15 - 25 form part of these financial statements.

The Magdi Yacoub Institute
Balance Sheet
As at 31st March 2021

	Notes	£	2021	£	£	2020	£
Fixed Assets							
Intangible fixed assets	7			4,201		4,209	
Tangible fixed assets	8			3,811,314		3,890,206	
				<u>3,815,515</u>		<u>3,894,415</u>	
Current Assets							
Stock			1,000		1,000		
Debtors	9		244,511		438,423		
Cash at bank and in hand			<u>1,141,681</u>		<u>861,349</u>		
			1,387,192		1,300,772		
Creditors: Amounts falling due within one year	10		<u>(244,695)</u>		<u>(112,848)</u>		
Net Current Assets				<u>1,142,497</u>		<u>1,187,924</u>	
Net Assets				<u><u>4,958,012</u></u>		<u><u>5,082,339</u></u>	
Funds							
Unrestricted funds							
- General	11			956,551		1,098,245	
- Designated	11			3,815,515		3,894,415	
Restricted funds	12			<u>185,946</u>		<u>89,679</u>	
				<u><u>4,958,012</u></u>		<u><u>5,082,339</u></u>	

These financial statements were approved by the Board of Trustees and authorised for issue on



Trustee & The Director of Research
Professor Sir Magdi Yacoub

Date: 19 December 2021

The accompanying notes on pages 15 - 25 form part of these financial statements.

Company Registration Number: 04061607

The Magdi Yacoub Institute
Statement of Cash Flows
For the year ended 31st March 2021

	Notes	2021 £	2020 £
Cash inflow used in operating activities			
Net cash generated by/(used in) operating activities	(i)	382,883	(93,050)
Cash flows used in investing activities			
Investment income		376	1,581
Acquisition of tangible fixed assets	8	(102,019)	(67,387)
Acquisition of intangible fixed assets	7	(1,380)	(825)
Disposals of intangible fixed assets	7	472	-
Cash flows used in investing activities		280,332	(159,681)
Net increase/(decrease) in cash and cash equivalents		280,332	(159,681)
Cash and cash equivalents at beginning of year		861,349	1,021,030
Cash and cash equivalents at end of year		1,141,681	861,349

(i) Reconciliation of net expenditure to net cash flow from operating activities:

	2021 £	2020 £
Net expenditure as per Statement of Financial Activities	(124,327)	(192,784)
Adjustments for:		
Depreciation charge	180,911	195,498
Amortisation charge	916	-
Interest income	(376)	(1,581)
Decrease/(Increase) in stock	-	523
Decrease/(Increase) in debtors	193,912	(86,258)
Increase/(Decrease) in creditors	131,847	(8,448)
Net cash generated by/(used in) operating activities	382,883	(93,050)

	As at 1 April 2020 £	Cash flows £	As at 31 March 2021 £
Analysis of net debt			
Cash at bank	861,349	280,332	1,141,681

The Magdi Yacoub Institute
Notes to the Financial Statements
For the year ended 31st March 2021

1 Accounting Policies

These financial statements are prepared on a going concern basis, under the historical cost convention.

The financial statements have been prepared in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). The Company is a public benefit entity for the purposes of FRS 102 and a registered charity established as a company limited by guarantee and therefore has also prepared its financial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) including Update Bulletin 2 and the Companies Act 2006.

The financial statements have been prepared in sterling, which is the functional currency of the entity. Monetary amounts in these financial statements are rounded to the nearest pound.

Going Concern

The trustees have assessed whether the use of the going concern basis is appropriate and have considered possible events or conditions that might cast significant doubt on the ability of the company to continue as a going concern. The trustees have made this assessment for a period of at least one year from the date of approval of the financial statements. In particular the trustees have considered the company's forecast and projections and have taken account of the COVID-19 pandemic. Donation income is the Institute's main source of income and often is reliant on large ad-hoc donations from donors from the wider network of the Institute's founder Professor Yacoub. The trustees have prepared a cash flow forecast covering a period of at least twelve months from the date of approval of these accounts and have concluded the Institute has adequate resources to continue in operation in this period. The company therefore continues to adopt the going concern basis in preparing its financial statements.

Income

Donations, Legacies and similar income

All income is recognised when there is entitlement to the funds, the receipt is probable and the amount can be measured reliably.

Legacies are recognised following probate and once there is sufficient evidence that receipt is probable and the amount of the legacy receivable can be measured reliably. Where entitlement to a legacy exists but there is uncertainty as to its receipt or the amount receivable, details are disclosed as a contingent asset until the criteria for income recognition are met.

Grants Receivable

Grants receivable are credited to the Statement of Financial Activities (SOFA) in the year for which they are received. Deferred income represents amounts received for future periods and is released to incoming resources in the period for which it has been received.

Expenditure

Expenditure is accounted for on an accruals basis and are recognised when there is a legal or constructive obligation to pay for the expenditure.

Expenditure on operational programmes is recognised in the period in which it is incurred. A designated fund is established for expenditure, which has been committed to projects, but remains unspent at the year end.

Raising Funds

These include the salaries, direct expenditure and overhead costs of the staff who promote fund-raising including events.

Charitable expenditure

These comprise of research costs. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

The Magdi Yacoub Institute

Notes to the Financial Statements

For the year ended 31st March 2021

1 Accounting Policies (continued)

Allocation of costs

All costs are allocated between expenditure categories of the SoFA on a basis to reflect the use of the resource. Costs relating to a particular activity are allocated directly, others are apportioned on a direct cost basis.

Governance costs

These include those costs associated with meeting the constitutional and statutory requirements of the charity and include the audit fees and the costs linked to the strategic management of the charity.

Stock

Stock is stated at the lower of cost and net realisable value.

Capitalisation and Depreciation of Tangible Fixed Assets

All assets costing more than £500 are capitalised at cost.

Depreciation is provided on all tangible fixed assets at rates calculated to write off their cost over their expected useful lives as follows:

Freehold Land	Land is not depreciated
Freehold Buildings	2% straight line
Furniture, Fittings and Equipment	25% reducing balance
Machinery	25% reducing balance

Financial Instruments

Cash and cash equivalents

Cash and cash equivalents include cash at banks and in hand and short term deposits with a maturity date of three months or less.

Debtors and creditors

Debtors and creditors receivable or payable within one year of the reporting date are carried at their transaction price. Debtors and creditors that are receivable or payable in more than one year and not subject to a market rate of interest are measured at the present value of the expected future receipts or payment discounted at a market rate of interest.

Pension

The organisation operates a defined contribution scheme where costs are charged to the Statement of Financial Activities as they become due.

Taxation

The charity is exempt from corporation tax under sections 466-497 of the Corporation Taxes Act 2010 as all its income is applied to charitable purposes.

Employee benefits

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

Fund Accounting

Funds held by the charity are:

Unrestricted general funds

These are funds which can be used in accordance with the charitable objects at the discretion of the trustees.

Designated Funds

These funds have been earmarked by the trustees for a particular purpose.

The Magdi Yacoub Institute

Notes to the Financial Statements

For the year ended 31st March 2021

1 Accounting Policies (continued)

Fund Accounting (continued)

Restricted Funds

These are funds that can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Foreign Currencies

Transactions in foreign currencies are recorded using the rate of exchange ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the rate of exchange ruling at the balance sheet date. Gains or losses on transactions are included in the Statement of Financial Activities.

Critical accounting estimates and areas of judgement

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

(a) Useful economic lives of tangible assets

The annual depreciation charge is sensitive to changes in the estimated useful economic lives of the assets. Useful economic lives are re-assessed annually and are amended where necessary to reflect current estimates based on the physical condition of the assets. See note 1 accounting policies for the useful economic lives of tangible assets.

2a) Grants and Donations

2021	Unrestricted	Restricted	2021 Total
	£	£	£
Heart Biotech	-	122,808	122,808
Imperial College London - BHF	-	24,659	24,659
Leducq Foundation	-	58,291	58,291
Magdi Yacoub Global Heart Foundation (MYGHF)	-	329,590	329,590
Recharges	290,656	-	290,656
Baxter Healthcare	-	9,892	9,892
Eva Pharma	125,000	-	125,000
CJRS grants	119,714	-	119,714
Other donations	24,114	-	24,114
	<u>559,484</u>	<u>545,240</u>	<u>1,104,724</u>

The Magdi Yacoub Institute
Notes to the Financial Statements
For the year ended 31st March 2021

2a) Grants and Donations (continued)

2020	Unrestricted	Restricted	2020 Total
	£	£	£
Canadian Cardio Society	3,788	-	3,788
Wedding Gift Registry	49,090	-	49,090
Heart Biotech	-	80,000	80,000
Imperial College London	-	10,718	10,718
Imperial College London - BHF	-	33,610	33,610
King Baudouin	120,118	-	120,118
Leducq Foundation	-	81,486	81,486
Al Alfi/Abu-Ghazaleh	382,695	-	382,695
Magdi Yacoub Global Heart Foundation (MYGHF)	-	67,847	67,847
Magdi Yacoub Foundation (MYF)	-	26,969	26,969
Recharges	306,541	-	306,541
Other donations	13,743	400	14,143
	-	-	-
	<u>875,975</u>	<u>301,030</u>	<u>1,177,005</u>

3 Investment Income and Interest

	2021	2020
	£	£
Bank interest	<u>376</u>	<u>1,581</u>

4 Expenditure

	Fundraising and Publicity	Research	Total 2021
2021	£	£	£
Staff costs	77,161	480,704	557,865
Travel	423	12,959	13,382
Research	638	205,546	206,184
Equipment	-	45,674	45,674
	<u>78,222</u>	<u>744,883</u>	<u>823,105</u>
Support costs:			
Bank charges	91	391	482
Accountancy	1,045	19,856	20,901
Legal and professional fees	216	4,113	4,329
Premises	2,074	39,397	41,471
Communications	1,325	33,809	35,134
Depreciation	-	180,911	180,911
Stationery	94	1,793	1,887
Insurance	1,203	22,852	24,055
Foreign exchange gains	-	65	65
Sundry	341	6,914	7,255
Governance (note 4a)	<u>77,794</u>	<u>12,038</u>	<u>89,832</u>
	<u>162,405</u>	<u>1,067,022</u>	<u>1,229,427</u>

The Magdi Yacoub Institute
Notes to the Financial Statements
For the year ended 31st March 2021

4 Expenditure (continued)

	Fundraising and Publicity £	Research £	Total 2020 £
2020			
Staff costs	68,906	546,692	615,598
Travel	1,627	61,139	62,766
Research	552	216,717	217,269
Equipment	-	58,258	58,258
Advertising	37	616	653
	<u>71,122</u>	<u>883,422</u>	<u>954,544</u>
Support costs:			
Bank charges	13	239	252
Accountancy	1,195	22,696	23,891
Legal and professional fees	227	4,363	4,590
Premises	3,243	58,970	62,213
Communications	1,076	26,038	27,114
Depreciation	-	195,497	195,497
Stationery	41	798	839
Insurance	910	17,289	18,199
Foreign exchange losses	-	(47)	(47)
Sundry	179	3,403	3,582
Governance (note 4a)	69,495	11,201	80,696
	<u>147,501</u>	<u>1,223,869</u>	<u>1,371,370</u>

Allocation of support

Support costs are allocated on a basis consistent with the use of resources.

4a Governance costs comprise of the following:

	2021 £	2020 £
Staff costs	77,161	68,906
Audit and accountancy	12,671	11,790
	<u>89,832</u>	<u>80,696</u>

5 Net expenditure for the year

	2021 £	2020 £
This is stated after charging:		
Depreciation	180,911	195,498
Amortisation	917	-
Auditors' remuneration (excluding VAT)		
Audit	10,350	10,050
Other services	1,320	1,700

The Magdi Yacoub Institute
Notes to the Financial Statements
For the year ended 31st March 2021

6 Staff Costs and Numbers

	2021	2020
	£	£
Staff costs were as follows:		
Gross salaries - administrative support	100,314	85,571
Gross salaries - research staff	297,456	302,235
Gross salaries - grants	20,745	38,233
Employer National Insurance	40,397	44,338
Pension costs	29,133	31,328
Research staff - Imperial College	37,011	62,099
Contractors	109,970	120,700
	<u>635,026</u>	<u>684,504</u>

The number of employees who were paid in excess of £60,000 (including benefits in kind) were:

	2021	2020
	No.	No.
£60,000 - £69,999	2	2
£70,000 - £79,999	1	1
	<u>3</u>	<u>3</u>

The pension contributions relating to the higher paid employees amounted to £16,010 (2020: £15,825) during the year.

No trustees or connected persons, received any remuneration during the period. One trustee (2020: One) was reimbursed £1,088 as travel and subsistence expenses (2020: £113) during the year.

The average monthly head count of employees are as follows:

	2021	2020
	No.	No.
Administration support	2	2
Research	9	9
	<u>11</u>	<u>11</u>

Key Management Personnel

The charity considers that the key management personnel comprise of the trustees and the senior management team, who are the trustees and the Chief Operating Officer. The total employee benefits including pension costs of the key management personnel were £79,004 (2020: £79,628).

7 Intangible Fixed Assets

	Website
	2021
	£
Cost	
At 1st April 2020	4,898
Additions	1,380
Disposals	(653)
At 31st March 2021	<u>5,625</u>
Amortisation	
At 1st April 2020	689
Charge	916
Disposals	(181)
At 31st March 2021	<u>1,424</u>
Net Book Value	
At 31st March 2021	<u>4,201</u>
At 31st March 2019	<u>4,209</u>

The Magdi Yacoub Institute
Notes to the Financial Statements
For the year ended 31st March 2021

8 Tangible Fixed Assets	Freehold Property	Fixtures and Fittings	Machinery	Total
Cost	£	£	£	£
At 1st April 20	5,280,222	1,230,099	480,352	6,990,673
Additions	-	10,501	91,518	102,019
At 31st March 2021	<u>5,280,222</u>	<u>1,240,600</u>	<u>571,870</u>	<u>7,092,692</u>
Depreciation				
At 1st April 20	1,694,242	1,072,369	333,856	3,100,467
Charge	98,804	41,199	40,908	180,911
At 31st March 2021	<u>1,793,046</u>	<u>1,113,568</u>	<u>374,764</u>	<u>3,281,378</u>
Net Book Value				
At 31st March 2021	<u>3,487,176</u>	<u>127,032</u>	<u>197,106</u>	<u>3,811,314</u>
At 31st March 2020	<u>3,585,980</u>	<u>157,730</u>	<u>146,496</u>	<u>3,890,206</u>

9 Debtors	2021	2020
	£	£
Trade debtors	181,246	403,147
Other debtors	238	2,312
Prepayments and accrued income	63,027	32,964
	<u>244,511</u>	<u>438,423</u>

10 Creditors: Amounts falling due within one year	2021	2020
	£	£
Trade creditors	75,779	38,344
Other Creditors	6,918	6,236
Taxation & Social Security	12,046	11,344
Accruals and deferred income (10a)	149,952	56,924
	<u>244,695</u>	<u>112,848</u>

10a) Deferred income in 2021 includes amounts received in advance of use of the research laboratories.

	Brought forward	Amount added	Amount released	Carried forward
Deferred income 2021	<u>3,749</u>	<u>1,404</u>	<u>(2,421)</u>	<u>2,732</u>
Deferred income 2020	<u>1,732</u>	<u>2,742</u>	<u>(725)</u>	<u>3,749</u>

The Magdi Yacoub Institute
Notes to the Financial Statements
For the year ended 31st March 2021

11 Unrestricted Funds 2021	Balance at 1st April 2020	Income	Expenditure	Transfers	Balance at 31st March 2021
	£	£	£	£	£
General	1,098,245	559,860	(693,673)	(7,881)	956,551
Designated:					
Fixed assets - Building	3,585,980	-	(98,804)	-	3,487,176
Fixed assets - Equipment	157,730	-	(41,199)	10,501	127,032
Fixed assets - Machinery	146,496	-	(40,908)	91,518	197,106
Fixed assets - Website	4,209	-	(1,388)	1,380	4,201
	3,894,415	-	(182,299)	103,399	3,815,515
Total	4,992,660	559,860	(875,972)	95,518	4,772,066

Unrestricted Funds 2020	Balance at 1st April 2019	Income	Expenditure	Transfers	Balance at 31st March 2020
	£	£	£	£	£
General	1,139,532	877,556	(875,370)	(43,473)	1,098,245
Designated:					
Fixed assets - Building	3,684,785	-	(98,805)	-	3,585,980
Fixed assets - Equipment	166,210	-	(49,681)	41,201	157,730
Fixed assets - Machinery	167,321	-	(47,013)	26,188	146,496
Fixed assets - Website	3,384	-	-	825	4,209
Kohl Group General Fund	90	-	(258)	168	-
	4,021,790	-	(195,757)	68,382	3,894,415
Total	5,161,322	877,556	(1,071,127)	24,909	4,992,660

Fixed Assets - Building

This fund represents the net book value of Phase II, Heart Science centre, Harefield which is owned by the charity.

Fixed Assets - Equipment/Machinery/Website

This fund represents the net book value of the remaining fixed assets (Equipment and Machinery) and intangible fixed assets.

Kohl Group General Fund

This fund provides for seminar support costs at the Heart Science Centre and minor general expenses of the Kohl Research Group.

Transfers

All transfers relate to costs for specific projects that have been met directly from other unrestricted funds and have therefore been reallocated to the correct fund.

The Magdi Yacoub Institute
Notes to the Financial Statements
For the year ended 31st March 2021

12 Restricted Funds 2021	Balance at 1st April 2020	Income	Expenditure	Transfers	Balance at 31st March 2021
	£	£	£	£	£
Heart Biotech Holdings 2019	23,899	122,808	(141,283)	(91,518)	(86,094)
Imperial College London - BHF	-	24,659	(24,659)	-	-
Leducq Foundation	-	58,291	(58,291)	-	-
New Cairo Heart Centre	65,327	-	-	-	65,327
Magdi Yacoub Global Heart Foundation	-	102,298	(102,298)	-	-
Magdi Yacoub Foundation	453	-	-	-	453
Magdi Yacoub Global Heart Foundation - IPS	-	227,292	(22,968)	-	204,324
Baxter Healthcare	-	9,892	(3,956)	(4,000)	1,936
	89,679	545,240	(353,455)	(95,518)	185,946

Restricted Funds 2020	Balance at 1st April 2019	Income	Expenditure	Transfers	Balance at 31st March 2020
	£	£	£	£	£
Heart Biotech Holdings 2019	65,937	80,000	(97,129)	(24,909)	23,899
Imperial College London - P67820	-	33,610	(33,610)	-	-
Imperial College London - Techcelerate	-	10,718	(10,718)	-	-
Leducq Foundation	60	81,486	(81,546)	-	-
New Cairo Heart Centre	38,358	26,969	-	-	65,327
Magdi Yacoub Global Heart Foundation - 2020	-	67,847	(67,847)	-	-
Magdi Yacoub Foundation	9,446	-	(8,993)	-	453
Other restricted donations	-	400	(400)	-	-
	113,801	301,030	(300,243)	(24,909)	89,679

Baxter Healthcare

This grant was given to support the research costs to evaluate Preveleak as a surgical sealant for aortic dissection repair.

Heart Biotech Holdings 2019

The Institute collaborates with Heart Biotech in developing a tissue engineered free-standing 3D valve that reproduces the hemodynamic function of a normal valve and therefore is ready for the next stage of validation.

Imperial College London - BHF

This BHF grant was given to support the research costs to investigate the Role of the Angiotensin II and Natriuretic Peptides in Aortic Valve Disease. The grant started in October 2020 and runs for 2 years.

Imperial College London - P67820

This BHF grant was given to support the research costs to investigate the role of the mechanosensitive ion channel Piezo 1 in human valve endothelial cells. The grant ended in January 2020.

Imperial College London - Techcelerate

The funds were given to support a staff member attendance on a Techcelerate course at Imperial college.

The Magdi Yacoub Institute
Notes to the Financial Statements
For the year ended 31st March 2021

12 Restricted Funds (continued)

Leducq Foundation

These funds are restricted to the project "Redox Regulation of Cardiomyocyte Renewal" in which the MYI is one of the participating institutions within the Leducq funded Transatlantic Network.

Magdi Yacoub Global Heart Foundation

These grants were given to support MYI during the Covid-19 pandemic.

Magdi Yacoub Global Heart Foundation - 2020

These funds were received to purchase imaging equipment and were fully utilised at year end.

Magdi Yacoub Global Heart Foundation - IPS

This fund is a two year project for Generation of AHC- 100 iPSC lines library.

Magdi Yacoub Foundation

This fund supports the laboratory costs, including minor equipment and travel for Ms Mona Allouba, a PhD Student under the supervision of Dr Paul Barton, Cardiovascular Genetics and Genomics Group.

New Cairo Heart Centre

Funds received towards building a new Cardiac Unit.

Transfers

Transfers relate to costs for specific projects that have been met directly from other unrestricted funds and have therefore been reallocated to the correct fund.

The Magdi Yacoub Institute
Notes to the Financial Statements
For the year ended 31st March 2021

13 Analysis of Net Assets between funds 2021

	General £	Designated £	Restricted £	Total 2021 £
Tangible fixed assets	-	3,815,515	-	3,815,515
Net Current Assets	956,551	-	185,946	1,142,497
At 31st March 2021	<u>956,551</u>	<u>3,815,515</u>	<u>185,946</u>	<u>4,958,012</u>

Analysis of Net Assets between funds 2020

	General £	Designated £	Restricted £	Total 2020 £
Tangible fixed assets	-	3,894,415	-	3,894,415
Net Current Assets	1,098,245	-	89,679	1,187,924
At 31st March 2020	<u>1,098,245</u>	<u>3,894,415</u>	<u>89,679</u>	<u>5,082,339</u>

14 Share Capital

The Magdi Yacoub Institute is a company limited by guarantee. The liability of the members of the charitable company is limited to £1 each.

15 Pension Scheme

The Foundation operates a defined contribution scheme for the employees. The assets of the scheme are administered by Aviva (formerly Friends Life) and are held in a separate fund.

The pension costs for the year were £29,133 (2020: £31,328) of which £3,958 (2020: £4,351) was unpaid at the year end and is included in creditors.

16 Capital Commitments

There were no capital commitments noted at year end (2020: £Nil).

17 Related Party Transactions

Costs of £278,851 (2020: £291,509) were incurred by Magdi Yacoub Institute (MYI) and recharged to Magdi Yacoub Foundation (MYF) as agreed between the entities. Dr Magdy Ishak is the Chairman of MYF and a trustee of MYI. At the year end a balance of £140,481 (2020: £412,213) was due from MYF.

MYI received two restricted grants of £30,000 and £92,808 totalling £122,808 (2020: £80,000) from Heart Biotech Holdings of which Dr. Magdy Ishak is the Chairman and where Professor Sir Magdi Yacoub is a Research Director. Dr. Magdy Ishak is the Chief Executive of MYI and Sir Magdi Yacoub is a trustee of MYI.

During the year MYI received two grants from the Magdi Yacoub Global Heart Foundation (MYGHF) of £102,298 covid grant and £227,292 IPS totalling £329,000 (2020: £67,847). Mr Magdy Ishak is the chairman and Sir Magdi Yacoub is a trustee of MYGHF whilst both are trustees of MYI.

18 Grants MYI board approved but not committed to

At 31 March 2021 the Magdi Yacoub Institute board has grants approved but not committed of £51,725 (2020: £67,488). These are unspent at the year end and are not included in these financial statements.